wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q37919869-E985342B-36F5-4284-B91E-48774396A4A7
Q37919869-E985342B-36F5-4284-B91E-48774396A4A7
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37919869-E985342B-36F5-4284-B91E-48774396A4A7
Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?
P2860
Q37919869-E985342B-36F5-4284-B91E-48774396A4A7
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37919869-E985342B-36F5-4284-B91E-48774396A4A7
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
aafd389102116855f6443522679cbd86dc483191
P2860
Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia.